Introduction
Hepatocellular carcinoma (HCC) is a highly lethal disease with a rising incidence. Around 746,000 people die of HCC across the world annually, making it the second leading cause of cancer death. 1 It is difficult to diagnose HCC early. Therefore, its highly malignant features and rapid progression result in poor outcome and prognosis. Despite adopting the Barcelona Clinic Liver Cancer strategy in HCC treatment, the overall 5-year survival remains poor at 20%. 2 Therefore, novel treatment strategies for HCC, especially for late-stage HCC, are urgently needed.
The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/ HGF) and its receptor c-mesenchymal-epithelial transition factor (c-Met) participate in cancer progression by enhancing several cancer hallmarks. [3] [4] [5] [6] In the case of solid tumors, hypoxia can enhance HGF/c-Met expression, 7, 8 which facilitates angiogenesis and stimulates the growth, locomotion, and invasion of cancer cells. In HCC, the protein level of c-Met is 25-100% higher than that in normal liver, 9 suggesting a promising target for HCC. The interruption of the HGF/c-Met axis is widely adopted as an anticancer strategy. Some c-Met inhibitors, such as tivantinib, golvatinib, and cabozantinib, have been described to interfere with the c-Met signaling pathway. 10, 11 However, the side effects and resistance of these inhibitors remain unresolved. Antibody-based approaches to interrupt the HGF/ c-Met interaction have been explored in the last few years. 12 However, the intrinsic agonistic activity of the bivalent monoclonal antibody (mAb) makes it difficult to develop a promising anti-c-Met mAb that can antagonize the dimerization and autophosphorylation of the receptor tyrosine kinase (RTK). 13, 14 A monovalent one-armed anti-c-Met antibody was produced using the knobs-into-holes technology. The binding affinity of the antibody to the extracellular part of c-Met was preserved, but the ability to induce c-Met dimerization was abolished. Onartuzumab (OA-5D5, MetMAb) is a onearmed humanized anti-c-Met antibody derived from an agonistic antibody 5D5. Onartuzumab has shown antitumor activity in multiple human tumor xenograft models, [15] [16] [17] including lung, colon, breast, stomach, and brain. However, it was not previously evaluated in HCC models.
In the present study, a monovalent anti-c-Met antibody was successfully prepared using the knobs-into-holes technology to potently inhibit HCC growth, migration, and angiogenesis in vitro and in vivo. Further, several mechanisms by which this antibody inhibited HCC progression were identified.
Materials and Methods
The lentiviral vectors for the expression of the monovalent antibody against the human c-mesenchymal-epithelial transition factor were constructed in the laboratory. The primers were synthesized by GENEWIZ Bio. (Suzhou, China) Phusion High-Fidelity Polymerase Chain Reaction (PCR) Master Mix, restriction enzymes, and T4 DNA ligase were procured from NEW ENGLAND BioLabs, Inc. (MA, USA). Bacteria competent cells, gel extraction kit, and plasmid Miniprep kit were purchased from Axygen Scientific, Inc. (CA, USA).
Antibodies and Reagents
The antibodies used for immunoblotting analysis were as follows: Phospho-Gab1 (Tyr307) Antibody#3234, Gab1
Antibody#3232, Phospho-Met (Tyr1234/1235) (D26) XP rabbit mAb#3077, Met (D1C2) XP rabbit mAb#8198, Akt (pan) (C67E7) rabbit mAb#4691, phospho-Akt (Ser473) (D9E) XP rabbit mAb#4060, p44/42 Mitogen-activated protein kinase (MAPK) (Erk1/2) (137F5) rabbit mAb#4695, phospho-p44/42 MAPK (Erk1/2) (Thr202/ Tyr204) (D13.14.4E) XP rabbit mAb#4370, beta-actin (13E5) rabbit mAb#4970, and anti-rabbit immunoglobulin G, horseradish peroxidase (HRP)-linked Antibody#7074 (all from Cell Signaling Technology, Inc., MA, USA). Beta-actin was used as the internal standard in this study.
Bivalent anti-c-Met antibodies were produced using the hybridoma method. BALB/c mice were immunized with the extracellular domain of human c-Met linked to His tag (c-Met ECD-His), and parental monoclonal antibodies were selected for their ability to bind to c-Met and inhibit the HGF/c-Met interaction. The monovalent one-armed anti-c-Met antibody was produced using the knobs-intoholes technology. 17 The anti-c-Met antibody heavy chain was modified to encode the T366S:L368A:Y407V mutations, and the Fc fragment was modified to contain the T366W mutation. The light chain, mutated heavy chain, and Fc fragment were co-transfected into HEK-293 cells. The products were purified with Ni Sepharose 6 Fast Flow (#17-5318-06, GE Healthcare., MA, USA).
Antibody Candidate Screening
The binding affinity of anti-c-Met antibodies was evaluated using enzyme-linked immunosorbent assay (ELISA) for the reactivity to c-Met ECD-His. The selected candidates were further evaluated using fluorescence-activated cell sorting (FACS) for the affinity to living cells. The antitumor activity of the antibodies was evaluated using a ligand-binding assay with ELISA for the ability to compete with HGF, Western blot for the inhibitory activity of c-Met phosphorylation, a 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8)-Cell Counting Kit-8 (CCK-8) for the anti-cell growth activity, Transwell assay for the anti-migration activity and tube formation assay for the anti-angiogenesis activity.
Cell Culture
HepG2 and HEK293 cells were obtained from the American Type Culture Collection (VA, USA). The cells were incubated with Dulbecco's modified Eagle's Medium (DMEM) (Gibco Co., Ltd, USA.) containing 10% fetal bovine serum (FBS, qualified, Australia#10099-141; Gibco Co., Ltd) in a humidified incubator in the presence of 5% CO 2 at 37°C. Human umbilical vein endothelial cells (HUVECs) were obtained from the Allcells Co., Ltd. (Shanghai, China). The cells were incubated with HUVEC complete medium (#H-004, Allcells Co., Ltd.).
Establishment of the c-Met Overexpressing and Depleted Cells
The genes of the extracellular domain ligated with the transmembrane domain of the human c-Met (prrl-c-Met-TM) and RNAi sequence of TCAACTTCTTTGTAGGCAATA (prrl-Hep G2-shc-Met) were cloned into the lentivirus plasmid. Chinese hamster ovary (CHO) and Hep G2 cells were transiently transfected with prrl-c-Met-TM and prrl-shc-Met respectively, using Lipofectamine 3000 (Thermo Fisher Scientific Co., Ltd, USA). The cells were harvested for flow cytometry analysis after 48-72 h of incubation.
Enzyme-Linked Immunosorbent Assay
The recombinant fusion protein encoding the c-Met ECD-His was plated onto a 96-well ELISA plate (Corning Co., Ltd. USA) at a concentration of 1 μg/mL. After overnight incubation at 4°C, the plates were washed with phosphatebuffered saline (PBS) containing 0.05% Tween-20, blocked with 1% BSA in PBS, and probed with recombinant HGF (0.1 μg/mL) or the anti-c-Met antibodies for 1 h, followed by incubation with an HRP-conjugated anti-human HGF antibody (American Qulex, CA, USA) or an HRP-conjugated secondary antibody. The reaction was visualized by adding 3,3′,5,5′-tetramethylbenzidine (Beyotime Biotechnology, Shanghai, China), and the absorbance was read at 450 nm using a Bio-Rad iMark microplate reader.
Cell Proliferation Assay
The cells were seeded in the 96-well plates and treated with HGF, antibody, or other reagents for 72 h. After the treatment, the cells were counted using a 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8)-Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). The average absorbance of the treated cells was detected using a Bio-Rad iMark Microplate Reader.
Cell Migration Assay
Transwell chambers were purchased from BD Biosciences (MA, USA). HepG2 cells (2.5 × 10 4 cells per well) were seeded into the upper chamber of the Transwell inserts and maintained at 37°C throughout the experiment. The cells were allowed to migrate toward the lower chamber in a medium containing either an HGF or an antibody for 24 h. The cell migration was evaluated after the crystal violet staining by counting cells in six randomly chosen fields.
Tube Formation Assay
Matrigel (Corning Inc., MA, USA) was dissolved at 4°C. Aliquots (100 μL/well) were added to the 96-well plates, which were incubated at 37°C overnight. HUVECs, resuspended at a concentration of 3 × 10 4 /100 μL in a medium containing HGF, antibody, or other reagents, were added to each Matrigel-coated well. After 18-20 h of incubation at 37°C, the cell capillary-like structure formation of HUVECs was assessed by microscopy, and the images of each well were obtained using a light microscope.
Flow Cytometric Analysis
The binding affinity of the antibody to the cell surface expressing c-Met was determined by flow cytometry analysis. Approximately 1 × 10 6 cells were harvested from a monolayer culture, washed, and incubated with a saturating amount (10 μg/mL) of primary antibody in PBS (pH 7.4) with 2% FBS (staining buffer) for 30 min on ice. The cells were then washed and stained with an Alexa Fluor 488-conjugated goat anti-mouse IgG1 secondary antibody (diluted 1:100; Invitrogen, USA) for 15 min on ice. The cells were subsequently incubated with a fluoresceinconjugated mAb for 30 min on ice. The cell suspension was washed three times with PBS and then analyzed using a FACS Calibur flow cytometer (BD Immunocytometry Systems, NJ, USA).
Immunoblotting Analysis
Total proteins were extracted from the treated cells using radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology; Cat No. P0013B). The concentrations were measured using a bicinchoninic acid (BCA)Protein Assay Kit (Beyotime Biotechnology; Cat. P0012, Lot No. 040717170810). After electrophoresis, the proteins were transferred onto an Immobilon-P Transfer Membrane (Millipore Corporation, USA; Cat No. IPVH00010, Lot No. K3EA8230FK) and finally detected using a Supersignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, USA; Cat No. 34096, Lot No. TC263090).
Xenograft Mouse Model
Eighteen 6-to 8-week-old BALB/c nude mice were purchased from SLRC Laboratory Animal Co., Ltd. (Shanghai, China) and housed in the specific-pathogen-free animal facility in Tongji University (Shanghai, China) for 1 week before the experiments. The mice had ad libitum access to filtered tap water in a specific-pathogen-free animal room under supervision. The facility staff monitored animal health care daily and took care of commercial feed supply, cleaning of cages and beddings, animal observation and report, and so forth. The animal care and animal experiments were approved by the Tongji University Laboratory Animal Care and Use Committee and performed according to the committee's guidelines. All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. HepG2 cells (5 × 10 6 cells/mouse) with Matrigel (Corning, NY, USA) were subcutaneously inoculated into the right flanks of mice (n = 6/group, 18 mice in total) to allow tumor isografts to grow to an approximate size of 50 mm 3 [tumor volume = (length × width × height)/2]. The mice were randomly assigned to treatment and control groups and received intraperitoneal injections of vehicle and 2E6 (5 and 10 mg/kg) twice a week for up to 4 months. Despite applying humane endpoints in the present study, no mice became severely ill or injured prior to the experimental endpoint. All mice were euthanized by the intraperitoneal injection of sodium pentobarbital (500 mg/kg, Sigma-Aldrich, MO, USA) at the end of the experiments.
Statistical Analysis
Data were statistically analyzed using GraphPad Prism 6 (Graph Pad, CA, USA). Differences between the antibodytreated and the control-treated groups were analyzed using the Student's t-test. A P value of less than 0.05 was considered to represent a significant difference.
Results

Generation and Characterization of the One-Armed Anti-c-Met Antibody
Monoclonal antibodies specific for c-Met were generated by immunizing BALB/c mice with a recombinant fusion protein encoding the extracellular domain of human c-Met linked to His tag (c-Met ECD-His) and screened for the competitive inhibitory capacity against HGF/c-Met interaction in a ligand-binding assay. The highly specific lead antibody 1H9D6, which inhibited the HGF binding to c-Met, was selected for further recombinant construction. Since the bivalent antibody caused ligand-independent RTK activation, some monovalent antibody structures were invented to develop an inhibitory RTK antibody, but its short half-life in vivo limited their broad application. The knobs-into-holes technology was employed to construct a one-armed antic-Met antibody to overcome the short half-life of the monovalent antibody, by introducing hole mutations (T366S, L368A, and Y407V) in the Fc of a full-length heavy chain and a knob mutation (T366W) in the single Fc fragment ( Figure 1A) . These mutations were expected to facilitate heterodimerization between a full-length heavy chain and a single Fc fragment and promote the assembly of the monovalent antibody. The one-armed anti-c-Met antibody 2E6 was generated in an eukaryotic cell line HEK293, which coexpressed the chimeric 1H9D6 light chain, a hole containing full-length heavy chain, and a knob containing Fc chain. The denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the one-armed anti-c-Met antibody 2E6 had a light chain (~30 kDa) and a heavy chain (~53 kDa), which were in accordance with the parental antibody 1H9D6 ( Figure 1B , lane 1), and Fc (~35 kDa) ( Figure 1B , lane 2). The larger molecular weight (MW) of the light chain and Fc than that was calculated from the protein sequence (24 kDa for the light chain and 25 kDa for Fc) indicated that the eukaryotic expression preserved the glycosylation of the antibody. Non-denaturing conditions result in a great error in the protein marker designed mainly for denaturing conditions. Hence, in the non-denaturing polyacrylamide gel electrophoresis, the parental antibody 1H9D6 was chosen as an additional indicator to calibrate the error ( Figure 1B, lane 1) . The results showed that the difference between the MWs of 1H9D6 and 2E6 was~52 kDa, which was in accordance with that calculated from protein sequences. Taken together, the monovalent antibody (~102 kDa), redundant heavy chain (~53 kDa), and reduced level of the light chain (~24 kDa) were detected for 2E6 ( Figure 1B, lane 2) .
The binding of the one-armed anti-c-Met antibody to the target was further detected. Like the parental antibody 1H9D6, 2E6 bound to immobilized c-Met ECD-His in a dose-dependent manner ( Figure 1C) . The EC50 was 0.2716nM for 1H9D6 and 1.758nM for 2E6. The variability likely resulted from the difference in the complementarity-determining region (CDR)/MW ratio. In a cell line HepG2 with the high expression of c-Met, the similar binding capacity of 2E6 and 1H9D6 was confirmed by flow cytometry analysis ( Figure 1D) .
To detect the specificity of 2E6, a full length Western blot was conducted with 2E6 on the lysates from (CHO), Henrietta Lacks (Hela), and Hep G2. The results showed the strong bands at~135kDa for the mature c-Met β subunit and the weaker bands at~100kDa for the underglycosylated c-Met in the blots of c-Met high-expressing cell lines, Hela and Hep G2. For the CHO blots, no obvious bands were detected with 2E6 ( Figure 2A Figure 2C ).
One-Armed Anti-c-Met Antibody Reduced the HGF/c-Met Signaling Axis
A one-armed anti-c-Met antibody, derived from a full-length antibody whose epitope overlapped with the HGF-binding site, was designed to antagonize the HGF/c-Met signaling axis by blocking the HGF/c-Met interaction. 2E6 was first tested for its ability to compete with HGF in a ligand-binding assay. As expected, 2E6 inhibited the recombinant HGF binding to immobilized Met ECD-HIS in a dose-dependent mode, with an EC50 value of 4.326nM. Similar results were obtained with the parental antibody 1H9D6, with an EC50 value of 2.159nM ( Figure 3A) . To confirm the competitive activity of 2E6 with HGF in living cells, the influence of HGF (10nM) on the reactivity of 2E6 (20nM) to the cell line HepG2 with the high expression of c-Met was examined by flow cytometry analysis. The presence of HGF resulted in a significant decrease in the reactivity of HepG2 with 2E6 ( Figure 3B ). To detect the effect of 2E6 on the HGF-induced phosphorylation of c-Met and downstream signaling pathways, the cellular kinase-targeting activity of HGF was verified in HepG2 cells. A time course of c-Met, Gab-1, Akt, and Erk1/2 phosphorylation after incubation with HGF (50 ng/mL) was detected. The results indicated a rapid and transient increase in HGF/c-Met signaling, and the maximal phosphorylation appeared in 5 min after HGF treatment ( Figure 4A ). Pretreatment with 2E6 (10nM) and a c-Met/ anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) PF-02341066 (1μM), which was used as positive control, caused a dramatic decrease in the c-Met, Gab-1, Akt, and Erk1/2 phosphorylation 5 min after HGF (0.5nM) stimulation at the same level ( Figure 4B ). These results indicated that the cellular kinase-targeting activity could be inhibited by antagonizing the HGF/c-Met interaction and inhibiting tyrosine kinase activity withone-armed anti-c-Met antibody.
Antitumor Activity of the One-Armed Anti-c-Met Antibody in HCC Cell Lines
The effect of 2E6 on the growth of HCC cell line HepG2 was investigated. In both HGF-treated or non-HGF-treated cells, 2E6 (1-25nM) significantly inhibited cell growth in a dosedependent manner ( Figure 5A ). Interestingly, treatment with exogenous HGF exerted a little effect on cell growth and the inhibition rate of 2E6. These results indicated that the onearmed anti-c-Met antibody most likely inhibited HepG2 proliferation by interfering with the HGF autocrine loop. The effect of 2E6 on the migration and invasion of a panel of HCC cell lines, including, HepG2, Huh-7, Hep 3B2 and SMMC-7721 cells was further investigated in a Transwell assay. In contrast to cell growth, the migration and invasion of HCC cells were strongly stimulated by exogenous HGF, and dramatically suppressed by 2E6 (1-25nM) treatment ( Figure 5B ). When the 2E6 concentration was more than 5nM, the number of migrated Hep G2 cells decreased even below the basal level. These results indicated that both exogenous and endogenous HGF-induced cell migration in HCC cells could be inhibited by 2E6.
One-Armed Anti-c-Met Antibody Reduced HGF-Induced Angiogenesis
The activation of c-Met plays the most crucial role in regulating tumor angiogenesis. Because HGF-induced c-Met activation eventually stimulates endothelial cell responses, 2E6 was tested for its ability to inhibit HGFinduced HUVEC responses. In the case of endothelial cell proliferation, a cell viability assay was conducted. HGF Figure 6A ). In the case of endothelial cell tube formation, an in vitro Matrigel angiogenesis assay was conducted. HGF-induced HUVEC tube formation (0.5nM) dramatically increased compared with the control, while 2E6 (2.5-10nM) inhibited HGFinduced HUVEC tube formation ( Figure 6B ).
One-Armed Anti-c-Met Antibody Inhibited HepG2 Tumor Xenograft Growth
The anticancer activity of 2E6 was evaluated in HepG2 xenografts in mice within 6 weeks of 2E6 injection. As shown in Figure 7A , the administration of 2E6 delayed the growth of HepG2 cells. 2E6 treatment dramatically inhibited xenograft tumor volumes ( Figure 7B ). Further, 5 mg/kg of 2E6 caused 44.5% ± 13.3% inhibition of tumor volumes, and 10 mg/kg of 2E6 caused 65.8% ± 12.5% inhibition of tumor volumes. The mouse body weights were almost unchanged between the groups, indicating that the administration of 2E6 was generally safe for the experimental mice (data not shown).
Discussion
C-Met and its ligand HGF are widely expressed and precisely regulated in normal tissues. In HCC, paracrine delivered HGF, autocrine loop formation, and overexpression of ligand and/or receptor cause inappropriate c-Met signaling. The upregulated c-Met pathway promotes aggressive oncogenic phenotypes, including cell migration and invasion capability, proliferation, and tumor angiogenesis. The present study showed that c-Met inhibition by a novel one-armed anti-c-Met antibody suppressed the oncogenic phenotypes of HCC in vitro and in vivo. These results indicated that the antibody targeted at the receptor might be able to overcome the overexpression of ligand and/or receptor in tumor tissues.
The inhibition of HGF/c-Met has been identified as a potential therapy for HCC. Several types of agents are under development for the c-MET signaling inhibitors, including HGF-neutralizing antibodies, HGF antagonists, Figure 4 The inhibition of the one-armed anti-c-Met antibody on the HGF/c-Met axis. Notes: (A) The time course of c-Met, Gab-1, Akt, and Erk phosphorylation in HepG2 cells after incubation with HGF (1nM). (B) Cells were treated with 2E6 (10nM) or PF-02341066 (1μM) for 120 min before stimulation with HGF (1nM) for 5 min. c-Met, Gab-1, Akt, and Erk phosphorylation levels were measured using immunoblotting. The results were the averages of duplicate from the representative of three independent experiments, the error bars represent the SD. Abbreviations: c-Met, c-mesenchymal-epithelial transition factor; HGF, hepatocyte growth factor; Gab-1, Grb2-associated binding protein 1; Akt, v-Akt gene expression protein, also referred to as PKB (Protein kinase B); Erk, Extracellular regulated protein kinases; PF-02341066: Crizotinib, a c-Met inhibitor; SD, standard deviation. and c-Met TKIs. However, for these inhibitors, especially for HGF antagonists and TKIs, the off-target activity, toxicity, and variation of the tumor c-Met status (gene mutation, gene amplification, and overexpression) often result in failure in clinical trials. Thus, highly selective antibodies are expected to overcome these problems. In the last few years, multiple antibody-based strategies were used to inhibit the HGF/c-Met axis. Anti-HGF antibodies that blocked the binding of human HGF to c-Met were investigated. Anti-HGF antibodies were proved to inhibit HGF-mediated c-Met phosphorylation, cell proliferation, survival, and invasion in vitro. These antibodies inhibited HGF-dependent autocrine-driven tumor growth and caused the significant regression of established U-87 MG tumor xenografts. 18 Meanwhile, approaches to develop inhibitory anti-c-Met monoclonal antibody have encountered a number of difficulties. Epitope difference may account for the different functional agonist properties of the anti-MET antibody. Only a few full-length and bivalent anti-MET monoclonal antibodies were reported to have an inhibitory effect. For example, R13, R28, and LY2875358 were reported to inhibit the HGF/c-Met interaction and the subsequent activation of c-Met, Akt, and Erk1/2, as well as HGF-induced migration and proliferation. 19, 20 Most c-Met antibodies have intrinsic agonistic activity resulting from their bivalent structure, which induces the dimerization and autophosphorylation of RTKs in a ligandindependent manner. The reconstruction of the anti-c-Met antibody to build a monovalent one-armed antibody is a widely accepted strategy to overcome the agonistic activity of anti-c-Met.
Recombinant human single-chain variable fragments (scFv) have been developed against various therapeutic targets for cancer treatments. 21 The specific binding of anti-c-Met scFv to c-Met can cause growth inhibition and induction of apoptosis pathways in tumor cells in vitro, [22] [23] [24] but its short half-life limits its application in vivo. To overcome this problem, the knobs-into-holes technology was adopted to construct a one-armed anti-c-Met antibody with a long half-life. In the last few years, Genentech (CA, USA) has developed a recombinant humanized monoclonal monovalent anti-c-Met antibody onartuzumab (OA-5D5, MetMAb) and investigated its preclinical activity in glioblastoma (GBM), pancreatic cancer, breast cancer, and nonsmall-cell lung cancer (NSCLC). However, no study explored the effect of the one-armed anti-c-Met antibody on HCC.
In this study, a novel one-armed anti-c-Met antibody 2E6 was constructed, which had similar affinity to c-Met as that of onartuzumab, to confirm the antitumor activity of the monovalent anti-c-Met antibody in HCC. As the HGF/c-Met axis is a key pathway in HCC, the antagonistic activity of 2E6 was first detected based on the c-Met signaling pathway. The HGF/c-Met axis usually comprises HGF binding, c-Met dimerization and phosphorylation, activation of adaptor proteins, and subsequent multiple signaling pathways, among which PI3K/ Akt and Ras/Erk-MAPK contribute to HGF-induced invasion and migration. 25 In this study, the time course of the phosphorylation of c-Met, Gab-1, Erk, and Akt after HGF stimulation was verified in an HCC cell line HepG2, which was then used to investigate the influence of 2E6 on the HGF/c-Met axis. A c-Met/ALK TKI, PF-02341066 (Crizotinib), was chosen as a positive control. The results showed that the one-armed anti-c-Met antibody markedly inhibited the HGF/c-Met signaling pathway to the same extent as TKI. Multiple antitumor effects of this antibody were further investigated in HepG2 cells. Taken together, the results suggested that 2E6 had the antiproliferative capacity that contributed to the inhibition of tumor growth and antimigratory effects in HCC. Another mechanism that seems to have contributed to the antitumor effect of the 2E6 antibody is the inhibition of tumor angiogenesis. The HGF-induced proliferation and tube formation of HUVECs were reduced by 2E6 treatment. The signaling through c-Met is known to directly mediate proangiogenic effects, such as endothelial cell migration, proliferation, and formation of three-dimensional tubes. The interruption of HGF/c-Met signaling likely also accounts for the inhibitory effect of the one-armed anti-c-Met antibody on tumor vasculature.
Although the antitumor activity of anti-c-Met antibodies was proved by researchers, the development of the antibody-based c-Met inhibitor is still controversial. Apart from the HGF-dependent activation, non-HGF factors can cause c-Met activation, such as overexpression-induced activation, mutation-induced activation, or transactivation of other receptors. Most anti-c-Met antibodies were developed as potential therapeutics antagonizing HGF binding and therefore inhibiting the HGF-dependent, but not the non-HGF-dependent, c-Met activity. Some of the results of the present study suggested that the c-Met antibody might inhibit non-HGF-induced c-Met activation. (1) In the absence of exogenous HGF, 2E6 still inhibited HepG2 proliferation ( Figure 4A ). (2) With the increasing concentration of 2E6, HepG2 migration decreased even below the basal level ( Figure 4B ). These phenomena might be explained by interfering the autocrine loop of HGF. However, while further investigating the transcription level of HGF in cultured HepG2 cells, the real-time PCR showed much lower HGF mRNA level compared with the c-Met mRNA level (data not shown). Hence, it was speculated that the basal c-Met activity in HepG2 cells might also originate from non-HGF factors and the diverse epitopes on antigen surface might offer the opportunity for different monoclonal anti-c-Met antibodies to mask the interface between c-Met and activating factors in an HGFdependent or a non-HGF-dependent manner.
Conclusion
In conclusion, the present study confirmed that activated c-Met was one of the promising targets of anticancer drugs. The monovalent anti-c-Met antibody is an attractive strategy of drug development for c-Met inhibition, which has the potential to overcome the intrinsic agonistic activity of the full-length bivalent anti-c-Met antibody.
